Cibc World Market Inc. reduced its position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Rating) by 7.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,170 shares of the company's stock after selling 960 shares during the period. Cibc World Market Inc.'s holdings in Allogene Therapeutics were worth $139,000 at the end of the most recent quarter.
A number of other hedge funds have also made changes to their positions in ALLO. Navalign LLC increased its position in shares of Allogene Therapeutics by 1.5% during the second quarter. Navalign LLC now owns 75,365 shares of the company's stock worth $859,000 after purchasing an additional 1,094 shares in the last quarter. Oppenheimer & Co. Inc. boosted its stake in Allogene Therapeutics by 10.0% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 16,550 shares of the company's stock worth $189,000 after purchasing an additional 1,500 shares during the last quarter. US Bancorp DE grew its holdings in shares of Allogene Therapeutics by 41.9% during the second quarter. US Bancorp DE now owns 5,474 shares of the company's stock worth $63,000 after buying an additional 1,616 shares in the last quarter. Victory Capital Management Inc. grew its holdings in shares of Allogene Therapeutics by 13.3% during the first quarter. Victory Capital Management Inc. now owns 14,335 shares of the company's stock worth $120,000 after buying an additional 1,688 shares in the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in shares of Allogene Therapeutics by 1.2% in the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 156,700 shares of the company's stock valued at $1,428,000 after buying an additional 1,874 shares during the last quarter. Institutional investors and hedge funds own 84.81% of the company's stock.
Get Allogene Therapeutics alerts:Allogene Therapeutics Price Performance
NASDAQ ALLO opened at $10.60 on Friday. Allogene Therapeutics, Inc. has a 12 month low of $6.43 and a 12 month high of $19.25. The stock has a market capitalization of $1.53 billion, a P/E ratio of -4.82 and a beta of 0.59. The firm's 50-day moving average is $10.50 and its two-hundred day moving average is $11.42.
Allogene Therapeutics (NASDAQ:ALLO – Get Rating) last issued its quarterly earnings data on Wednesday, November 2nd. The company reported ($0.58) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.04. Allogene Therapeutics had a negative net margin of 126,580.16% and a negative return on equity of 37.74%. During the same period last year, the company posted ($0.57) EPS. As a group, analysts anticipate that Allogene Therapeutics, Inc. will post -2.38 EPS for the current year.Analyst Upgrades and Downgrades
A number of equities analysts recently weighed in on ALLO shares. JMP Securities restated a "buy" rating and set a $23.00 price target on shares of Allogene Therapeutics in a research report on Tuesday, September 27th. B. Riley dropped their price target on Allogene Therapeutics from $21.00 to $18.00 and set a "buy" rating for the company in a research report on Thursday, September 22nd. HC Wainwright reduced their price objective on Allogene Therapeutics from $43.00 to $29.00 and set a "buy" rating on the stock in a research report on Monday. Truist Financial dropped their target price on Allogene Therapeutics to $29.00 in a report on Tuesday, August 23rd. Finally, Raymond James lowered Allogene Therapeutics from an "outperform" rating to a "market perform" rating in a report on Wednesday, August 10th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat.com, Allogene Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $25.70.
Allogene Therapeutics Profile
(Get Rating)
Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL.
See Also
- Get a free copy of the StockNews.com research report on Allogene Therapeutics (ALLO)
- Microsoft Shares: Is it Time to Back Up the Truck?
- Three CBD Stocks to Dominate a Budding Industry
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Institutional Support for Analog Devices Remains High
- Is the 60/40 Portfolio Mix Still in Vogue?
Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.